Market
What will be the first year US sales of Datroway by end of 2025?
2
Resolution / Starting Odds
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Financial reports and sales data from AstraZeneca and Daiichi Sankyo
Story
FDA Approves Datroway for Advanced HR-Positive, HER2-Negative Breast Cancer
Jan 21, 2025, 02:03 AM
AstraZeneca and Daiichi Sankyo's new cancer drug, Datroway (datopotamab deruxtecan), has received FDA approval for treating advanced HR-positive, HER2-negative breast cancer. The drug, an antibody-drug conjugate targeting the TROP2 protein, is designed for patients whose cancer has progressed after endocrine therapy and chemotherapy. Results from the TROPION-Breast01 Phase III trial showed Datroway reduced the risk of disease progression or death by 37% compared to chemotherapy, with a median progression-free survival of 6.9 months versus 4.9 months for chemotherapy. While the drug demonstrated significant efficacy in progression-free survival, it fell short of statistical significance in overall survival improvement. Datroway is part of AstraZeneca's broader oncology strategy, marking its eighth new medicine approved in the U.S. as part of its goal to launch 20 new drugs by 2030. The drug's approval adds to the growing list of targeted therapies for breast cancer, offering a new treatment option for patients with limited alternatives.
View original story
Similar markets
40-60% • 25%
20-40% • 25%
Less than 20% • 25%
More than 60% • 25%
10% to 20% • 25%
More than 30% • 25%
20% to 30% • 25%
Less than 10% • 25%
Japan • 25%
European Union • 25%
China • 25%
Other • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
30% to 39% • 25%
40% or more • 25%
20% to 29% • 25%
$100 million to $200 million • 25%
More than $300 million • 25%
$201 million to $300 million • 25%
Less than $100 million • 25%
Decrease • 25%
Increase by less than 10% • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
More than $4 billion • 25%
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%